Inhibitors of Sphingolipid Metabolism
857392 (R)-FTY720-OMe
View857393 THI
View857395 GT-11
View860455 N-C12-deoxysphingosine
View860456 N-C16-deoxysphingosine
View860461 N-C12-desoxymethylsphinganine
View860466 N-C12-desoxymethylsphingosine
View860462 N-C16-deoxysphinganine
View860463 N-C16-desoxymethylsphinganine
View860467 N-C16-desoxymethylsphingosine
View860464 N-C24:1-deoxysphinganine
View860457 N-C24:1-deoxysphingosine
View860465 N-C24:1-desoxymethylsphinganine
View860468 N-C24:1-desoxymethylsphingosine
View860493 1-deoxysphinganine
View860470 1-deoxysphingosine
View860473 1-desoxymethylsphinganine
View860477 1-desoxymethylsphingosine
View860479 Adamantanyl Galactosyl(ß) Ceramide
View860480 C10 bisphosphonate
View860488 Safingol
View860771 Enigmol(2S,3S,5S)
View860772 N-C6-Enigmol(2S,3S,5S)
View860792 C23 Galactosyl(ß) Ceramide (d18:1/23:0)
ViewLewis, A.C., Wallington-Beddoe, C.T., Powell, J.A., et al. Targeting sphingolipid metabolism as an approach for combination therapies in hematological malignancies. Cell Death Discov. 4, 72 (2018). https://doi.org/10.1038/s41420-018-0075-0